Autocatalytic maturation, physical/chemical properties, and crystal structure of Group N HIV-1 protease: Relevance to drug resistance

Protein Science

Volumn 19, Issue 11, 2010, Pages 2055-2072

  Sayer, Jane M ^a   Agniswamy, Johnson ^b   Weber, Irene T ^b   Louis, John M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Calorimetry; Crystal structure; Dimer dissociation; Enzyme kinetics; HIV AIDS; Polyprotein processing; Retroviral protease

Indexed keywords

AMINO ACID; DARUNAVIR; DIMER; MONOMER; PROTEINASE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CALORIMETRY; CATALYSIS; CRYSTAL STRUCTURE; DIMERIZATION; DISSOCIATION CONSTANT; ENZYME KINETICS; FRACTIONATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR STABILITY; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PH; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CALORIMETRY; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME STABILITY; ESCHERICHIA COLI; HIV PROTEASE; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE ANNOTATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78349272713     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.486     Document Type: Article

References (54)

1. Bodelle P, Vallari A, Coffey R, McArthur CP, Beyeme M, Devare SG, Schochetman G, Brennan CA (2004) Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon. AIDS Res Hum Retroviruses 20:902-908. (Pubitemid 39121211)
2. Kane CT, Montavon C, Toure MA, Faye MA, Ndiaye AG, Diallo AG, Ndoye I, Liegeois F, Delaporte E, Mboup S, Peeters M (2001) Full-length genome sequencing of HIV type 1 group O viruses isolated from a heterosexual transmission cluster in Senegal. AIDS Res Hum Retroviruses 17:1211-1216. (Pubitemid 32881587)
3. Plantier JC, Leoz M, Dickerson JE, De OF, Cordonnier F, Lemee V, Damond F, Robertson DL, Simon F (2009) A new human immunodeficiency virus derived from gorillas. Nat Med 15:871-872.
4. Vallari A, Bodelle P, Ngansop C, Makamche F, Ndembi N, Mbanya D, Kaptue L, Gurtler LG, McArthur CP, Devare SG, Brennan CA (2010) Four new HIV-1 group N isolates from Cameroon: prevalence continues to be low. AIDS Res Hum Retroviruses 26:109-115.
5. Yamaguchi J, Coffey R, Vallari A, Ngansop C, Mbanya D, Ndembi N, Kaptue L, Gurtler LG, Bodelle P, Schochetman G, Devare SG, Brennan CA (2006) Identification of HIV type 1 group N infections in a husband and wife in Cameroon: viral genome sequences provide evidence for horizontal transmission. AIDS Res Hum Retroviruses 22:83-92. (Pubitemid 43201521)
6. Hatfield DL, Levin JG, Rein A, Oroszlan S (1992) Translational suppression in retroviral gene expression. Adv Virus Res 41:193-239.
7. Oroszlan S, Luftig RB (1990) Retroviral proteinases. Curr Top Microbiol Immunol 157:153-185.
8. Louis JM, Weber IT, Tozser J, Clore GM, Gronenborn AM (2000) HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv Pharmacol 49:111-146.
9. Leis J, Baltimore D, Bishop JM, Coffin J, Fleissner E, Goff SP, Oroszlan S, Robinson H, Skalka AM, Temin HM (1988) Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol 62:1808-1809.
10. Louis JM, Clore GM, Gronenborn AM (1999) Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat Struct Biol 6:868-875.
11. Louis JM, Ishima R, Torchia DA, Weber IT (2007) HIV-1 protease: structure, dynamics, and inhibition. Adv Pharmacol 55:261-298.
12. Wensing AM, van Maarseveen NM, Nijhuis M (2010) Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res 85:59-74.
13. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD (2008) Update of the drug resistance mutations in HIV-1. Top HIV Med 16:138-145.
14. Brower ET, Bacha UM, Kawasaki Y, Freire E (2008) Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 71:298-305. (Pubitemid 351347797)
15. Levy Y, Caflisch A, Onuchic JN, Wolynes PG (2004) The folding and dimerization of HIV-1 protease: evidence for a stable monomer from simulations. J Mol Biol 340:67-79. (Pubitemid 38739438)
16. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284. (Pubitemid 15151982)
17. Ceccherini-Silberstein F, Erba F, Gago F, Bertoli A, Forbici F, Bellocchi MC, Gori C, D'Arrigo R, Marcon L, Balotta C, Antinori A, Monforte AD, Perno CF (2004) Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS 18:F11-F19. (Pubitemid 39095777)
18. Ishima R, Torchia DA, Louis JM (2007) Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor. J Biol Chem 282:17190-17199. (Pubitemid 47093202)
19. Louis JM, Ishima R, Aniana A, Sayer JM (2009) Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease. Protein Sci 18:2442-2453.
20. Louis JM, Oroszlan S, Tozser J (1999) Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. J Biol Chem 274:6660-6666. (Pubitemid 29111086)
21. Mildner AM, Rothrock DJ, Leone JW, Bannow CA, Lull JM, Reardon IM, Sarcich JL, Howe WJ, Tomich CS, Smith CW (1994) The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 33:9405-9413.
22. Ishima R, Torchia DA, Lynch SM, Gronenborn AM, Louis JM (2003) Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J Biol Chem 278:43311-43319. (Pubitemid 37345952)
23. Szeltner Z, Polgar L (1996) Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration. J Biol Chem 271:5458-5463. (Pubitemid 26083878)
24. Sayer JM, Liu F, Ishima R, Weber IT, Louis JM (2008) Effect of the active-site D25N mutation on the structure, stability and ligand binding of the mature HIV-1 protease. J Biol Chem 283:13459-13470.
25. Sayer JM, Louis JM (2008) Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Proteins 75:556-568.
26. Lam PY, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong YN (1994) Rational design of potent, bioavailable, non-peptide cyclic ureas as HIV protease inhibitors. Science 263:380-384. (Pubitemid 24067944)
27. Velazquez-Campoy A, Freire E (2006) Isothermal titration calorimetry to determine association constants for high-affinity ligands. Nat Protoc 1:186-191.
28. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA (2004) Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 78:12012-12021. (Pubitemid 39390785)
29. Hoffman NG, Schiffer CA, Swanstrom R (2003) Covariation of amino acid positions in HIV-1 protease. Virology 314:536-548. (Pubitemid 37206360)
30. Zoete V, Michielin O, Karplus M (2002) Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. J Mol Biol 315:21-52. (Pubitemid 34722109)
31. Sanches M, Krauchenco S, Martins NH, Gustchina A, Wlodawer A, Polikarpov I (2007) Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. J Mol Biol 369:1029-1040. (Pubitemid 46754060)
32. Coman RM, Robbins AH, Fernandez MA, Gilliland CT, Sochet AA, Goodenow MM, McKenna R, Dunn BM (2008) The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Biochemistry 47:731-743. (Pubitemid 351195444)
33. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW (2005) Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2:325-337.
34. Kantor R, Katzenstein D (2003) Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 5:25-35. (Pubitemid 36873892)
35. Ode H, Matsuyama S, Hata M, Neya S, Kakizawa J, Sugiura W, Hoshino T (2007) Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. J Mol Biol 370:598-607. (Pubitemid 46901071)
36. Clemente JC, Moose RE, Hemrajani R, Whitford LR, Govindasamy L, Reutzel R, McKenna R, Agbandje-McKenna M, Goodenow MM, Dunn BM (2004) Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. Biochemistry 43:12141-12151. (Pubitemid 39280558)
37. Hong L, Zhang XC, Hartsuck JA, Tang J (2000) Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci 9:1898-1904.
38. Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW, Weber IT (2006) Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem 49:1379-1387. (Pubitemid 43271890)
39. Agniswamy J, Weber IT (2009) HIV-1 protease: structural perspectives on drug resistance. Viruses 1:1110-1136.
40. Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT (2004) High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 338:341-352. (Pubitemid 38447090)
41. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H (2003) Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 47:3123-3129. (Pubitemid 37229567)
42. Liu F, Kovalevsky AY, Tie Y, Ghosh AK, Harrison RW, Weber IT (2008) Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. J Mol Biol 381:102-115.
43. Tang C, Louis JM, Aniana A, Suh JY, Clore GM (2008) Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease. Nature 455:693-696.
44. Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR (1998) Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. Biochemistry 37:2105-2110. (Pubitemid 28119284)
45. Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H (2007) Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 282:28709-28720. (Pubitemid 47606016)
46. Lindhofer H, von der Helm K, Nitschko H (1995) In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Virology 214:624-627.
47. Sluis-Cremer N, Tachedjian G (2002) Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem 269:5103-5111. (Pubitemid 35340819)
48. Uhlikova T, Konvalinka J, Pichova I, Soucek M, Krausslich HG, Vondrasek J (1996) A modular approach to HIV-1 proteinase inhibitor design. Biochem Biophys Res Commun 222:38-43. (Pubitemid 26152204)
49. Todd MJ, Semo N, Freire E (1998) The structural stability of the HIV-1 protease. J Mol Biol 283:475-488.
50. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data in oscillation mode. Methods Enzymol 276:307-326.
51. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61:458-464.
52. Storoni LC, McCoy AJ, Read RJ (2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60:432-438.
53. Sheldrick GM, Schneider TR (1997) High resolution refinement. Methods Enzymol 277:319-343.
54. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.